- Home
- Publications
- Publication Search
- Publication Details
Title
Discovery and characterization of olokizumab
Authors
Keywords
-
Journal
mAbs
Volume 6, Issue 3, Pages 773-781
Publisher
Informa UK Limited
Online
2014-03-20
DOI
10.4161/mabs.28612
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate
- (2012) P Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Identifying bottlenecks in transient and stable production of recombinant monoclonal-antibody sequence variants in chinese hamster ovary cells
- (2012) Megan Mason et al. BIOTECHNOLOGY PROGRESS
- Evolving Molecular Targets in the Treatment of Nonmalignant Gastrointestinal Diseases
- (2012) D A Katzka et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- Conservation of Functional Sites on Interleukin-6 and Implications for Evolution of Signaling Complex Assembly and Therapeutic Intervention
- (2012) Vaclav Veverka et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A Systematic Comparison of Free and Bound Antibodies Reveals Binding-Related Conformational Changes
- (2012) I. Sela-Culang et al. JOURNAL OF IMMUNOLOGY
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- IL-6/IL-6 receptor system and its role in physiological and pathological conditions
- (2011) Masahiko Mihara et al. CLINICAL SCIENCE
- Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer
- (2011) K. Fizazi et al. EUROPEAN JOURNAL OF CANCER
- Inflammatory Cytokines in Systemic Lupus Erythematosus
- (2011) Kim Ohl et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Constraining Enzyme Conformational Change by an Antibody Leads to Hyperbolic Inhibition
- (2011) David Oyen et al. JOURNAL OF MOLECULAR BIOLOGY
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Interleukin-6: From identification of the cytokine to development of targeted treatments
- (2010) Eric Assier et al. JOINT BONE SPINE
- MolProbity: all-atom structure validation for macromolecular crystallography
- (2009) Vincent B. Chen et al. ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY
- Therapeutic antibodies: successes, limitations and hopes for the future
- (2009) Patrick Chames et al. BRITISH JOURNAL OF PHARMACOLOGY
- Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor
- (2009) Jean-Michel Dayer et al. RHEUMATOLOGY
- IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system
- (2009) Misato Hashizume et al. RHEUMATOLOGY INTERNATIONAL
- High-Throughput Screening for High Affinity Antibodies
- (2009) Simon Tickle et al. Journal of the Association for Laboratory Automation.
- Inhibition of Interleukin-6-Transsignaling via gp130-Fc in Hemorrhagic Shock and Sepsis
- (2008) Soeren Torge Mees et al. JOURNAL OF SURGICAL RESEARCH
- IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF- and IL-17
- (2008) M. Hashizume et al. RHEUMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started